AI product ChatPRD has shut down its free trials. The stated reason was service abuse, but the deeper issue is that some users turned trial credits into a resellable AI resource. The “free for growth” model has now reached a clear cost boundary.
What this is
ChatPRD is an AI platform that helps product managers turn ideas into product requirement documents. Founder Claire Vo said some groups register accounts in bulk, exhaust free credits, and then resell access to the resulting capabilities. Others have used the platform to take on commercial work such as Roblox and Fortnite map production.
She also observed that abusers repeatedly submitted SVG images of “a pelican riding a bicycle” to analyze the generative characteristics of different models. This is essentially using prompts—text used to instruct a model—to probe the identity of the underlying model. More concerning, the credits did not originate from genuine user demand, but the platform still had to bear the service and inference costs they generated.
Industry view
We believe ending free trials across the board is reasonable, but not necessarily the optimal endpoint. It can stop the immediate bleeding, yet it may also penalize early users still evaluating a product and raise the barrier to trying AI products. More mature approaches typically include device verification, detection of anomalous usage, credit-to-account binding, and tiered risk controls.
The risk is equally clear: once free credits can be resold, a gray market emerges around model usage volume. The more a platform depends on low-cost trials for customer acquisition, the more readily it outsources those costs to abusers. Those opposed to closing trials argue that overly strict limits weaken product distribution and the platform’s ability to identify promising users. The real challenge is not choosing one side of this binary, but distinguishing legitimate heavy use from organized arbitrage.
Impact on regular people
For enterprise IT: When procuring AI services, organizations cannot focus only on unit prices and test credits. They must also examine free-trial policies, account-sharing rules, resale restrictions, and responsibility for anomalous usage, or they may end up bearing inference costs incurred by others.
For individual professionals: There will be fewer opportunities to evaluate AI tools through free trials. Individuals will find it harder to conduct low-cost experiments by exploiting trial credits, making product selection increasingly dependent on formal subscriptions, team allocations, and enterprise purchasing.
For the consumer market: As free access shrinks, some consumer AI products may raise prices or shorten trial periods. Whether pricing actually improves, however, will depend on whether platforms can effectively identify and block account and credit resale.